Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

BRIC diagnostic imaging markets to reach $7.6B by 2018

The diagnostic imaging markets in Brazil, Russia, India and China—known as the BRIC markets, are expected to grow at a compound annual growth rate of 10.5 percent, reaching $7.6 billion within the next four years.

Thumbnail

SPECT Alzheimer’s imaging gains more momentum

PET has dominated the amyloid imaging ring for several years now, but a preclinical study is showing some signs that SPECT could give PET a run for its money eventually, especially in translational research, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

Thumbnail

Protein relays how patients will respond to cancer immunotherapy

A protein that suppresses immune response could tell researchers how patients taking a novel cancer immunotherapy will fare, Yale officials announced Nov. 26. The discovery could predict immune response in the treatment of a wide variety of cancers.

Thumbnail

Biogen to take anti-amyloid drug to late stage trial

Cambridge, Mass., based biomedical company Biogen Idec announced encouraging results of a phase II drug targeting amyloid in Alzheimer’s patients at a Deutsche Bank conference in Boston today.

Blood biomarkers tip off pre-malignant cancers

Early detection of blood cancers may be getting a big push with the discovery of a pre-cancerous state of genetic mutation in lymphomas, leukemia, myelodysplastic syndrome and other blood diseases. The biomarker is easily detectable in peripheral blood samples, according to two major studies published online Nov. 26 in the New England Journal of Medicine.

Thumbnail

Frost & Sullivan honors new Philips PET/CT

Philips Healthcare has won the title of the 2014 North America Award for Technology Innovation Leadership from the market research firm Frost & Sullivan based on the integrated technology of the Vereos digital PET/CT system, Frost & Sullivan officials announced Nov. 26.

Thumbnail

Theranostic nanomedicine: Q&A with Weibo Cai, PhD

As the use of theranostic nanoparticles in nuclear medicine and molecular imaging expands, it becomes clearer which technologies will have enough traction to be translated to clinical practice. Molecular Imaging caught up with Weibo Cai, PhD, associate professor and head of the University of Wisconsin Molecular Imaging and Nanotechnology Lab in Madison, to find out more about the leading research in theranostic nanomedicine.

Philips partners with Image Stream Medical to expand its integration solutions for image-guided minimally invasive therapies

Royal Philips, a leader in image-guided therapies, announced that it has signed an agreement with Image Stream Medical (ISM) that allows Philips to further expand its integration solutions for its hybrid suite and interventional lab solutions with integrated video and live streaming capabilities. As part of the agreement, Philips has acquired a minority stake in ISM. Financial terms of the agreement were not disclosed.